Related references
Note: Only part of the references are listed.Molecular diagnostics of gliomas: the clinical perspective
Ghazaleh Tabatabai et al.
ACTA NEUROPATHOLOGICA (2010)
Molecular diagnostics of gliomas: state of the art
Markus J. Riemenschneider et al.
ACTA NEUROPATHOLOGICA (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
Lucie Karayan-Tapon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Relationship between nucleosome positioning and DNA methylation
Ramakrishna K. Chodavarapu et al.
NATURE (2010)
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J. Dunn et al.
BRITISH JOURNAL OF CANCER (2009)
STAT3 Regulation of Glioblastoma Pathogenesis
Nuria la Iglesia et al.
CURRENT MOLECULAR MEDICINE (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
The DNA-encoded nucleosome organization of a eukaryotic genome
Noam Kaplan et al.
NATURE (2009)
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Sibille Everhard et al.
NEURO-ONCOLOGY (2009)
Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma
N. Zeng et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
What controls nucleosome positions?
Eran Segal et al.
TRENDS IN GENETICS (2009)
Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma -: Relationship between immunohistochemistry and methylation analysis
Ken Sasai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents
Bernd Kaina et al.
DNA REPAIR (2007)
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis
Thomas Mikeska et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Clinical significance of EGFR amplification and the aberrant EGFRVIII transcript in conventionally treated astrocytic gliomas
L Liu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island
W Zhao et al.
JOURNAL OF BIOCHEMISTRY (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Generating mutations but providing chemosensitivity:: the role of O6-methylguanine DNA methyltransferase in human cancer
M Esteller et al.
ONCOGENE (2004)
CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration
KK Bhakat et al.
CARCINOGENESIS (2003)
Cryopreservation of viable human glioblastoma xenografts
HM Goike et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2000)
Share Paper
